Biogen

Yahoo Finance • 20 days ago

UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026

Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks. Continue Reading... Full story

Yahoo Finance • 27 days ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and stren... Full story

Yahoo Finance • 30 days ago

Catalyst Watch: Santa Claus Effect, M&A votes on Electronic Arts and TrueCar, index shuffling

[Futuristic display screen with a bar graph and colorful spreadsheet financial data] matejmo Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that... Full story

Yahoo Finance • 30 days ago

Biogen (BIIB) Stock Trades Up, Here Is Why

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 2.8% in the morning session after RBC Capital reiterated an "Outperform" rating and a $210 price target on the stock, naming it a top large-cap pick for 2026. The firm... Full story

Yahoo Finance • last month

HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, citing concerns that BIIB’s reliance on... Full story

Yahoo Finance • last month

MicroStrategy retains place in key index despite delisting threats

Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful in retaining its spot in the Nasdaq 100 (NDQ). A benchmark stock market index in the U.S., the Nasdaq 100 tracks... Full story

Yahoo Finance • last month

Lululemon Set to Exit Nasdaq 100 as Index Adds New Members

This article first appeared on GuruFocus. lululemon athletica inc. (LULU, Financials) is among the companies set to leave the Nasdaq 100 Index as part of the benchmark's annual reconstitution, according to an announcement released Friday.... Full story

Yahoo Finance • last month

Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions

[The NASDAQ Stock Exchange headquarters in New York, USA] JHVEPhoto Six companies, including Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) and Seagate Technology Holdings (STX [https://seekingalpha.com/symbol/STX])... Full story

Yahoo Finance • last month

Annual Changes to the Nasdaq-100 Index®

Nasdaq, Inc. NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December... Full story

Yahoo Finance • last month

Fed Cuts Rates for Third Time This Year, Signals One More in 2026

The S&P 500 Index ($SPX) (SPY) today is down up +0.34%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.67%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.01%. In a divided vote, the Federal Reserve approved a third 25-ba... Full story

Yahoo Finance • last month

Stock Investors are Cautious Ahead of FOMC Results and Powell Comments

The S&P 500 Index ($SPX) (SPY) today is down by -0.06%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.26%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.50%.  December E-mini S&P futures (ESZ25) are down -0.08%, and Dece... Full story

Yahoo Finance • last month

Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Oppenheimer upgraded GE Vernova(GEV) t... Full story

Yahoo Finance • last month

Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More

Thinkstock Quick Read It’s likely that the Federal Reserve Chairman Jay Powell will announce a 25-basis-point rate cut this afternoon. Traders are worried sticky inflation and a slowly improving outlook for jobs could be the tailwind for... Full story

Yahoo Finance • last month

Great Point Partners Acquires a Majority Stake in Lenis Group, a Full-Service Specialty Pharmaceutical Commercialization and Distribution Partner

Former CEO of Biogen, Michel Vounatsos, Appointed Board Chairman of Lenis GREENWICH, Conn. & LJUBLJANA, Slovenia, December 10, 2025--(BUSINESS WIRE)--Great Point Partners ("GPP" or "the Firm"), a Greenwich-based private investment firm fo... Full story

Yahoo Finance • last month

HSBC highlights one pharma stock to buy and one to sell for 2026

Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook. The change... Full story

Yahoo Finance • last month

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbache... Full story

Yahoo Finance • last month

Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.

The addition of well-respected biotech expert strengthens one of Oppenheimer's longest-standing franchise areas NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Opp... Full story

Yahoo Finance • last month

Is Alnylam Pharmaceuticals a Millionaire Maker?

Key Points Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising. Whether or not Alnylam is a millionaire maker, the stock should be able to generate exceptional long-term returns.10 sto... Full story

Yahoo Finance • last month

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?

Key Points Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reaction suggests. There are still good reason... Full story

Yahoo Finance • last month

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvement... Full story